Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.

Article Details

Citation

Copy to clipboard

Bouerat L, Fensholdt J, Liang X, Havez S, Nielsen SF, Hansen JR, Bolvig S, Andersson C

Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.

J Med Chem. 2005 Aug 25;48(17):5412-4.

PubMed ID

16107139 [ View in PubMed

]

Abstract

The known KDR inhibitor SU5416 and several analogues of the indolin-2-one family were surprisingly found to be highly efficacious in the EAE model, an established model for multiple sclerosis. The high in vivo effect could be correlated to in vitro inhibition of the pro-inflammatory cytokine IL-2. Activity following po administration was obtained with several analogues and via the use of prodrugs.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Semaxanib	Vascular endothelial growth factor receptor 2	IC 50 (nM)	230	N/A	N/A	Details
Vatalanib	Vascular endothelial growth factor receptor 2	IC 50 (nM)	63	N/A	N/A	Details